Ixabepilone

伊沙匹隆

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameIxabepilone
Drug Alias Name伊莎匹隆ixabepilona依沙比酮ixabepilonum埃坡霉素 +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTubulin polymerisation inhibitors
TargetsTubulin
Therapy Area/IndicationsMetastatic breast cancerCNS Embryonal TumorSolid tumours +[79] 
Global Approved IndicationsBreast Neoplasms
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2007/10/16
Country/TerritoryCzechiaBelgiumCanada +[42] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPending
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesR-Pharm Us Llc
Inactive CompaniesNational Institutes Of Health Clinical Center (Cc)Bristol Myers Squibb SrlcompanyUniversity of Texas Southwestern Medical Center +[12] 
Active IndicationsBreast Neoplasms
Inactive IndicationsMetastatic breast cancerCNS Embryonal TumorSolid tumours +[78] 

Other Information

ATC CodeL01DC04
Related LinksWikipediaDrugBankKEGG